Eloralintide Explained: The NEW Weight-Loss Drug With 20% Results (Not a GLP-1) скачать в хорошем качестве

Eloralintide Explained: The NEW Weight-Loss Drug With 20% Results (Not a GLP-1)

Eloralintide is a new once-weekly amylin receptor agonist developed by Eli Lilly that’s showing up to 20% weight loss in Phase 2 clinical trials. Unlike GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound, Eloralintide targets the amylin pathway, offering a completely different mechanism for appetite control, satiety, and metabolic improvement. In this video, we break down how Eloralintide works, what the Phase 2 results revealed, safety and side effects, cardiometabolic benefits, and why experts believe amylin drugs may become the next major class in obesity treatment. We also look ahead to Phase 3 trials and the potential for combination therapy with GLP-1 and GIP agonists. If you’re interested in new weight-loss medications, future obesity treatments, or the science behind appetite and metabolism, this deep dive is for you. Resources: New weight-loss shot shows major fat reduction, but experts urge caution - https://www.foxnews.com/health/new-we... New weight loss drug, taken once weekly, leads to 20% weight loss in trial - https://www.medicalnewstoday.com/arti... Disclaimer: This video is based on my personal experience with Zepbound (tirzepatide) and my informal research into GLP-1 medications. I am not a medical professional—just a GLP-1 patient passionate about learning and sharing information. The content provided is for informational purposes only and should not be taken as medical advice. Always consult a qualified healthcare provider before starting or changing any medication or treatment. Individual results and side effects may vary. #Eloralintide #AmylinAgonist #WeightLossDrugs #ObesityTreatment #Ozempic #Wegovy #Mounjaro #Zepbound #Semaglutide #Tirzepatide #MedicalWeightLoss #MetabolicHealth #EliLilly #ObesityScience